Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDMX: Extension of Triamcinolone for Diabetic Macular Oedema
NCT00148330Phase 3Completed
- Sponsor
- University of Sydney
- Start
- May 2005
- Primary completion
- Jul 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of triamcinolone in diabetic macular edema (DME), sponsored by University of Sydney. Primary endpoints: Increase of ≥5 letters on a LogMAR chart at 5 years and Incidence of moderate or severe adverse events. Started May 2005; status: completed.
02
Drugs
triamcinolone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00148330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148330.